BACKGROUND: Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined. AIM: We sought to validate these associations and to explore their impact on treatment response to peginterferon and ribavirin therapy. METHODS: A total of 972 G1 HCV-infected Caucasian patients were genotyped for the SNPs rs12979860 (IL28B) and rs2896019 (PNPLA3). Multivariable analysis tested IL28B and PNPLA3 for association with the presence of any steatosis (>0 %); clinically significant steatosis (>5 %); steatosis severity (grade 0-3/4); and the interacting associations of the SNPs and hepatic steatosis to sustained viral response (SVR). RESULTS: IL28B and PNPLA3 polymorphisms were associated with the presence of any steatosis (rs12979860, p = 1.87 × 10(-7); rs2896019, p = 7.56 × 10(-4)); clinically significant steatosis (rs12979860, p = 1.82 × 10(-3); rs2896019, p = 1.27 × 10(-4)); and steatosis severity (rs12979860, p = 2.05 × 10(-8); rs2896019, p = 2.62 × 10(-6)). Obesity, hypertriglyceridemia, hyperglycemia, liver fibrosis, and liver inflammation were all independently associated with worse steatosis. Hepatic steatosis was associated with lower SVR, and this effect was attenuated by IL28B. PNPLA3 had no independent association with SVR. CONCLUSIONS: IL28B and PNPLA3 are associated with hepatic steatosis prevalence and severity in Caucasians with G1 HCV, suggesting differing potential genetic risk pathways to steatosis. IL28B attenuates the association between steatosis and SVR. Remediable metabolic risk factors remain important, independently of these polymorphisms, and remain key therapeutic goals to achieve better outcomes for patients with HCV-associated hepatic steatosis.
BACKGROUND: Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined. AIM: We sought to validate these associations and to explore their impact on treatment response to peginterferon and ribavirin therapy. METHODS: A total of 972 G1 HCV-infected Caucasian patients were genotyped for the SNPs rs12979860 (IL28B) and rs2896019 (PNPLA3). Multivariable analysis tested IL28B and PNPLA3 for association with the presence of any steatosis (>0 %); clinically significant steatosis (>5 %); steatosis severity (grade 0-3/4); and the interacting associations of the SNPs and hepatic steatosis to sustained viral response (SVR). RESULTS:IL28B and PNPLA3 polymorphisms were associated with the presence of any steatosis (rs12979860, p = 1.87 × 10(-7); rs2896019, p = 7.56 × 10(-4)); clinically significant steatosis (rs12979860, p = 1.82 × 10(-3); rs2896019, p = 1.27 × 10(-4)); and steatosis severity (rs12979860, p = 2.05 × 10(-8); rs2896019, p = 2.62 × 10(-6)). Obesity, hypertriglyceridemia, hyperglycemia, liver fibrosis, and liver inflammation were all independently associated with worse steatosis. Hepatic steatosis was associated with lower SVR, and this effect was attenuated by IL28B. PNPLA3 had no independent association with SVR. CONCLUSIONS:IL28B and PNPLA3 are associated with hepatic steatosis prevalence and severity in Caucasians with G1 HCV, suggesting differing potential genetic risk pathways to steatosis. IL28B attenuates the association between steatosis and SVR. Remediable metabolic risk factors remain important, independently of these polymorphisms, and remain key therapeutic goals to achieve better outcomes for patients with HCV-associated hepatic steatosis.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: L F Hourigan; G A Macdonald; D Purdie; V H Whitehall; C Shorthouse; A Clouston; E E Powell Journal: Hepatology Date: 1999-04 Impact factor: 17.425
Authors: Ke-Qin Hu; Namgyal L Kyulo; Eric Esrailian; Kevin Thompson; Resa Chase; Donald J Hillebrand; Bruce A Runyon Journal: J Hepatol Date: 2004-01 Impact factor: 25.083
Authors: I J Hickman; A D Clouston; G A Macdonald; D M Purdie; J B Prins; S Ash; J R Jonsson; E E Powell Journal: Gut Date: 2002-07 Impact factor: 23.059
Authors: Alexander Monto; Keyur Patel; Alan Bostrom; Stephen Pianko; Paul Pockros; John G McHutchison; Teresa L Wright Journal: Hepatology Date: 2004-03 Impact factor: 17.425
Authors: Heather M Patton; Keyur Patel; Cynthia Behling; David Bylund; Lawrence M Blatt; Marc Vallée; Shanon Heaton; Andrew Conrad; Paul J Pockros; John G McHutchison Journal: J Hepatol Date: 2004-03 Impact factor: 25.083
Authors: Amit G Singal; Hema Manjunath; Adam C Yopp; Muhammad S Beg; Jorge A Marrero; Purva Gopal; Akbar K Waljee Journal: Am J Gastroenterol Date: 2014-01-21 Impact factor: 10.864
Authors: Melanie E Garrett; Manal F Abdelmalek; Allison Ashley-Koch; Michael A Hauser; Cynthia A Moylan; Herbert Pang; Anna Mae Diehl; Hans L Tillmann Journal: J Hepatol Date: 2012-10-11 Impact factor: 25.083